Skip to main content

Table 1 General characteristics of included studies

From: Meta-analysis of effect of vernakalant on conversion of atrial fibrillation

Study N Treatment groups   Subject characteristics No. with conversion
   Regimen n Goal follow-up time Atrial fibrillation time Age (Years) Men (%) n/N %
Camm 2011 232 Vernakalant 116 1 week AF 3 to 48 63 63 60/116 51.7%
   3 mg/kg IVI f/b    hrs     
   2 mg/kg if        
   required 15 min        
   later       6/116 5.2%
   Amiodarone 5 mg/kg 60-min IVI f/b 50 mg IVI over additional 60 min 116       
Pratt 2010 239 Vernakalant 118 30 days AF 3hrs to 63 65 47/118 40%
   3 mg/kg IVI f/b    45 days     
   2 mg/kg if        
   required 15 min       4/121 3%
   later        
   Placebo 121       
Roy 2004 56 Vernakalant 18 1 week AF 3 to 72 64 61 2/18 11%
   0.5 mg/kg IVI f/b    hrs     
   1.0 mg/kg if        
   required 30min 18      11/18 61%
   later        
   Vernakalant        
   2.0 mg/kg IVI f/b 3.0 mg/kg if required 30 min later Placebo 20      1/20 5%
Roy 2008 336 Vernakalant 221 30 days AF 3 hrs 62 69 83/221 37.6%
   3 mg/kg IVI f/b    to 45 days     
   2 mg/kg if        
   required 15 min        
   later       3/115 2.6%
   Placebo 115       
Stiell 2010 290 Vernakalant 229   AF 3 to 48   69 136/229 59.4%
   3 mg/kg IVI f/b    hrs     
   2 mg/kg if   1 week   59    
   required 15 min        
   later 61      3/61 4.9%
   Placebo